常规诊疗中不符合随机对照试验标准的重性抑郁患者比例及结局:一项全国性登记研究
该研究基于芬兰和瑞典的全国性健康登记数据,评估了接受维持抗抑郁治疗的成年非精神病性重性抑郁障碍(MDD)患者中不符合随机对照试验(RCT)入组标准的比例及其结局。结果显示超过三分之一(芬兰33.5%,瑞典35.3%)的患者不符合RCT标准,且这些患者发生精神科住院或自杀未遂复合结局的风险是符合标准者的两倍以上(芬兰HR=2.44,瑞典HR=2.61)。
要点
- 超过三分之一的MDD维持治疗患者因共病等原因不符合RCT入组标准。
- 不符合RCT标准的患者发生精神科住院或自杀未遂的风险增加一倍以上。
- 约三分之一的复合不良结局可归因于RCT不合格因素。
核心结论
- 常规诊疗中超过三分之一的MDD患者不符合RCT标准,且其不良结局风险显著更高。
- 需要更包容的RCT入组标准并结合真实世界数据以提高证据外推性。
研究设计与样本
- 基于芬兰(2004-2018)和瑞典(2006-2021)全国性健康登记数据的队列研究,纳入接受维持抗抑郁单药治疗的成年非精神病性MDD患者。
- 通过多学科专家共识制定标准化RCT入排标准,将患者分类为RCT合格或不合格,随访6个月。
主要发现
- 芬兰队列73,720人,瑞典队列135,092人。
- RCT不合格比例:芬兰33.5%,瑞典35.3%。
- 复合主要结局(精神科住院或自杀未遂)风险:不合格组 vs 合格组,芬兰HR=2.44(95%CI:2.15-2.76),瑞典HR=2.61(95%CI:2.37-2.87)。
- 复合主要结局归因于RCT不合格因素的比例:芬兰32.5%(95%CI:27.9-37.1),瑞典36.2%(95%CI:32.6-39.8)。
关键数值与推荐
- RCT不合格最常见原因为共病(严重躯体疾病、其他精神障碍或物质使用障碍)。
- 不合格组治疗改变风险略高但显著。
临床怎么用
- 临床应意识到RCT证据可能不适用于超过三分之一的真实世界MDD患者。
- 对不符合RCT标准的患者需加强监测和个体化治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Randomized controlled trials (RCTs) are the foundation of current clinical treatment guidelines. However, they may not reflect real-world populations, due to strict eligibility criteria. We determined the proportion of individuals with major depressive disorder (MDD) receiving maintenance antidepressant treatment in routine care who would be ineligible for RCTs, and compared their outcomes with those who were eligible. Utilizing specialized health care registers in Finland (2004-2018) and Sweden (2006-2021), we identified adults diagnosed with non-psychotic MDD (ICD-10: F32, F33) who were stabilized on maintenance antidepressant monotherapy. Through multidisciplinary expert consensus on latest meta-analytic evidence, we derived a standardized list of RCT inclusion and exclusion criteria. These criteria were systematically applied to classify individuals as RCT-eligible or RCT-ineligible. We then used Cox proportional models to derive hazard ratios (HRs) of a composite primary outcome of hospitalization due to any psychiatric reason or suicide attempt, and all-cause mortality, during a 6-month follow-up. Secondary outcomes were treatment changes (i.e., discontinuation, switch or augmentation) and psychiatric sick leave ≥2 weeks. A total of 73,720 individuals in Finland and 135,092 in Sweden were included. More than one third of patients with MDD (33.5% in Finland and 35.3% in Sweden) were found to be ineligible for RCTs. The most common reasons for ineligibility were comorbidities (serious somatic disease, other psychiatric disorders, or substance use disorder). RCT-ineligible individuals had more than twice the risk of the composite primary outcome compared to eligible individuals (HR=2.44, 95% CI: 2.15-2.76 in Finland; HR=2.61, 95% CI: 2.37-2.87 in Sweden). Approximately one third of the composite primary outcome was attributable to RCT-ineligibility factors (32.5%, 95% CI: 27.9-37.1 for Finland; 36.2%, 95% CI: 32.6-39.8 for Sweden). Risk of treatment change was slightly but significantly higher in ineligible individuals. Findings were consistent in a wide range of sensitivity analyses. We conclude that more inclusive eligibility criteria for RCTs, and their integration with real-world data, are needed to improve the generalizability of antidepressant trial evidence and MDD clinical treatment guidelines.
引用
- Hamina A, Pinzón-Espinosa J, Taipale H, et al. Representation and outcomes of individuals with major depression in routine care who are ineligible for randomized controlled trials: a nationwide register-based study. World Psychiatry. 2026. PMID: 41536102. doi:10.1002/wps.70013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。